Jointown(SH:600998)2015-08-24 16:00Financial Performance - The company's operating revenue for the first half of 2015 reached ¥23.89 billion, an increase of 19.99% compared to ¥19.91 billion in the same period last year[17]. - Net profit attributable to shareholders was ¥250.56 million, reflecting a growth of 19.90% from ¥208.96 million in the previous year[17]. - The net profit after deducting non-recurring gains and losses was ¥225.62 million, which is a 28.82% increase from ¥175.14 million year-on-year[17]. - The company achieved operating revenue of 23.894 billion yuan, operating profit of 344 million yuan, and net profit of 253 million yuan, representing year-on-year growth of 19.99%, 49.28%, and 20.10% respectively[27]. - The company's main business revenue reached 23.867 billion yuan, with a main business profit of 1.744 billion yuan, reflecting growth of 20.00% and 32.22% year-on-year[29]. - The company reported a net cash flow from operating activities of -¥2.82 billion, a decline of 65.41% compared to -¥1.71 billion in the same period last year[17]. - The company reported a significant increase in inventory, which stood at RMB 6.17 billion, down slightly from RMB 6.31 billion, indicating a decrease of about 2.3%[124]. - The total comprehensive income for the first half of 2015 was CNY 230,152,330.26, compared to CNY 152,018,601.66 in the previous year, indicating a significant increase of 51.4%[134]. Assets and Liabilities - The company's total assets increased by 16.91% to ¥28.21 billion from ¥24.13 billion at the end of the previous year[17]. - The company's total liabilities reached RMB 19.70 billion, compared to RMB 16.04 billion at the beginning of the year, marking an increase of around 22.5%[125]. - The company's cash and cash equivalents decreased to RMB 2.88 billion from RMB 3.59 billion, a decline of about 19.6%[124]. - The total equity attributable to shareholders rose to RMB 8.15 billion from RMB 7.80 billion, showing an increase of approximately 4.5%[126]. - The company's long-term equity investments grew to RMB 615.45 million from RMB 174.31 million, representing an increase of about 253.5%[124]. Revenue Sources - The sales revenue from Western and traditional Chinese medicine reached 20.654 billion yuan, with a gross profit of 1.350 billion yuan, marking an 18.66% and 29.54% increase year-on-year[29]. - The pharmaceutical industry achieved sales revenue of 302 million yuan, up 22.71% from 246 million yuan year-on-year, with a gross profit of 56.18 million yuan, reflecting a 17.59% increase from 47.75 million yuan last year[33]. - Sales to secondary and higher-level hospitals reached 4.32 billion yuan, a 40.85% increase from 3.068 billion yuan year-on-year, with over 2,900 secondary and higher-level hospital clients at the end of the reporting period[34]. - The online B2C e-commerce business generated sales of 219 million yuan, a 36.88% increase year-on-year, although it incurred a loss of 24.44 million yuan due to ongoing investments in team building and technology development[34]. Investments and Expansion - The company completed the registration and approval for a financial leasing company with a registered capital of 3 billion yuan, in which the company holds a 15% stake[26]. - The company launched the "Jiuzhou Tianrun" brand in traditional Chinese medicine, expanding its business layout across various sectors[25]. - The company is awaiting the issuance of 1.5 billion yuan in convertible bonds approved by the China Securities Regulatory Commission[25]. - The company has established 66 subsidiaries that have obtained the new GSP certification, enhancing its operational capabilities[25]. - The company has made several joint ventures and acquisitions, including a CNY 45,000 million investment in Hubei Financial Leasing Co., accounting for 15% of the registered capital[61]. Corporate Governance and Compliance - The company has strengthened its corporate governance by adhering to relevant laws and regulations, holding 3 board meetings and 3 shareholder meetings during the reporting period[97]. - The company has committed to avoiding any actual or potential competition with major shareholders and actual controllers, ensuring compliance with industry regulations[93]. - The company has implemented a stock incentive plan with a vesting schedule of 30%, 30%, and 40% over 12, 24, and 36 months for key management personnel[94]. - The company has disclosed its commitment to timely information disclosure and investor relations management, enhancing transparency[97]. Shareholder Information - The total number of shares increased from 1,643,074,834 to 1,647,009,434, with an increase of 3,934,600 shares, representing 0.24% of the total shares before the increase[100][102]. - The largest shareholder, Shanghai Hongkang Industrial Investment Co., Ltd., holds 433,129,118 shares, accounting for 26.36% of the total shares[108]. - The company has a total of 41,541 shareholders as of the end of the reporting period[106]. - The company reported a total of 80,108,991 restricted shares held by Qilu Securities, which will become tradable on March 14, 2017[111]. Research and Development - The company launched 10 new R&D projects during the reporting period, including the LMIS8.0 and DTP pharmacy management systems, and obtained 12 software copyrights and 3 utility model patents[36]. - The company's R&D expenditure increased by 100.12% to RMB 1,582.29 million, driven by the development of e-commerce technology[45]. Cash Flow and Financing - The overall cash flow from operating activities showed a negative net amount of RMB -282,086.13 million, worsening by 65.41% compared to the previous year[45]. - The net cash flow from financing activities was CNY 3,419,465,355.08, significantly higher than CNY 1,783,770,134.82 in the same period last year, showing an increase of 92.0%[138]. - The company received CNY 5,199,927,545.67 from borrowings, which is an increase from CNY 3,469,482,668.18 in the previous year[138].